Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Neurofibromin 1 (NF1) loss-of-function mutations are common in melanoma, leading to hyperactivated RAS signaling and tumor progression.
• NF1-mutant melanoma cells exhibit resistance to single-agent inhibitors targeting MEK, ERK, or PI3K/mTOR pathways.

Purpose of the Study:

• To identify novel therapeutic strategies for NF1-mutant melanoma.
• To investigate the efficacy of a targeted kinase inhibitor screen.

Main Methods:

• A targeted kinase inhibitor screen was conducted.
• A tool compound, MTX-216, was evaluated for its effects on NF1-mutant melanoma growth in vitro and in vivo.
• Single-cell analysis was performed to assess drug-induced cytotoxicity.
• The inhibitory effects of MTX-216 on PI3K and SYK were investigated.
• Gene expression analysis was performed to identify affected pathways.
• Combination therapies involving MEK or PI3K/mTOR inhibitors with SYK inhibitors or knockdown were tested.

Main Results:

• MTX-216 demonstrated significant efficacy in inhibiting NF1-mutant melanoma growth.
• Cytotoxicity induced by MTX-216 correlated with suppressed Ki-67 and S6 phosphorylation.
• MTX-216's efficacy depended on its dual inhibition of PI3K and SYK.
• MTX-216 suppressed genes involved in mitochondrial electron transport chain, linked to poor patient survival.
• Combination therapies targeting MEK or PI3K/mTOR with SYK inhibition reduced melanoma cell growth.

Conclusions:

• Spleen tyrosine kinase (SYK) represents a targetable vulnerability in NF1-mutant melanoma.
• MTX-216 exhibits potent antitumor activity by inhibiting both PI3K and SYK.
• Targeting SYK, potentially in combination with other inhibitors, offers a promising therapeutic avenue for NF1-mutant melanoma.